Heska Corporation (NASDAQ:HSKA) veterinary diagnostic specialist, is reporting second quarter earnings results on Tuesday 4th August 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.34 per share.
For the full year, analysts predict revenues of $ 175.66 million, while looking forward to loss of $ 1.02 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 175.00 million ~ $ 185.00 million
Click Here For More Historical Outlooks Of Heska Corporation
Previous Quarter Performance
Heska Corporation posted loss for the first quarter of $ 0.14 per share, from the revenue of $ 30.65 million. The quarterly revenues expanded 3.86 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.25 per share from $ 32.66 million in revenue. The bottom line results beat street analysts by $ 0.11 or 44.00 percent, at the same time, top line results fell short of analysts by $ 2.01 million or 6.15 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Heska Corporation
Stock Performance
According to the previous trading day, closing price of HSKA was $ 101.22, representing a 102.44 % increase from the 52 week low of $ 50.00 and a 8.73 % decrease over the 52 week high of $ 110.90.
The company has a market capital of $ 950.65 million and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”HSKA” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Heska Corporation will be hosting a conference call at 11:00 AM eastern time on 4th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.heska.com
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The companys Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops.
